Carcinoma-derived Interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Alfaro, Carlos ^a   Suárez, Natalia ^a,b   Martínez Forero, Ivan ^a   Palazón, Asís ^a   Rouzaut, Ana ^a   Solano, Sarai ^a   Feijoo, Esperanza ^a   Gúrpide, Alfonso ^b   Bolaños, Elixabet ^a,b   Erro, Lorena ^a   Dubrot, Juan ^a   Hervás Stubbs, Sandra ^a   Gonzalez, Alvaro ^b   Perez Gracia, Jose Luis ^b   Melero, Ignacio ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CYCLOPHOSPHAMIDE; GEMCITABINE; GLYCOPROTEIN P 15095; INTERLEUKIN 8; NEUTRALIZING ANTIBODY; CHEMOTACTIC FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL STIMULATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DESENSITIZATION; DOSE RESPONSE; FEMALE; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MONOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; DRUG SCREENING; HUMAN; IMMUNOLOGY; INJECTION; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT; NEOPLASM; NEUTROPHIL; PATHOLOGY; T LYMPHOCYTE; TRANSPLANTATION; TUMOR CELL LINE;

MUS;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOTACTIC FACTORS; DENDRITIC CELLS; HUMANS; INJECTIONS; INTERLEUKIN-8; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; NEOPLASMS; NEUTROPHILS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952659848     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017922     Document Type: Article

References (56)

1. Feijoo E, Alfaro C, Mazzolini G, Serra P, Penuelas I, et al. (2005) Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 116: 275-281.
2. Mazzolini G, Alfaro C, Sangro B, Feijoo E, Ruiz J, et al. (2005) Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 23: 999-1010.
3. Xie K, (2001) Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391.
4. Sallusto F, Palermo B, Lenig D, Miettinen M, Matikainen S, et al. (1999) Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 29: 1617-1625.
5. Sozzani S, Luini W, Borsatti A, Polentarutti N, Zhou D, et al. (1997) Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol 159: 1993-2000.
6. Fan X, Patera AC, Pong-Kennedy A, Deno G, Gonsiorek W, et al. (2007) Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. J Biol Chem 282: 11658-11666.
7. Sallusto F, Lanzavecchia A, (1999) Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J Exp Med 189: 611-614.
8. Martin-Fontecha A, Lanzavecchia A, Sallusto F, (2009) Dendritic cell migration to peripheral lymph nodes. Handb Exp Pharmacol pp. 31-49.
9. MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, et al. (2003) Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198: 615-621.
10. Verdijk P, Aarntzen EH, Punt CJ, de Vries IJ, Figdor CG, (2008) Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther 8: 865-874.
11. Huarte E, Tirapu I, Arina A, Vera M, Alfaro C, et al. (2005) Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. Expert Opin Biol Ther 5: 7-22.
12. Bachmann MF, Kopf M, Marsland BJ, (2006) Chemokines: more than just road signs. Nat Rev Immunol 6: 159-164.
13. Waugh DJ, Wilson C, (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14: 6735-6741.
14. Murdoch C, Muthana M, Coffelt SB, Lewis CE, (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8: 618-631.
15. Schraufstatter IU, Trieu K, Zhao M, Rose DM, Terkeltaub RA, et al. (2003) IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor. J Immunol 171: 6714-6722.
16. Lin WW, Karin M, (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183.
17. Rolny C, Capparuccia L, Casazza A, Mazzone M, Vallario A, et al. (2008) The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med 205: 1155-1171.
18. Ueda T, Shimada E, Urakawa T, (1994) Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29: 423-429.
19. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70: 1063-1071.
20. Baggiolini M, Moser B, Clark-Lewis I, (1994) Interleukin-8 and related chemotactic cytokines. The Giles Filley Lecture. Chest 105: 95S-98S.
21. Baggiolini M, Loetscher P, (2000) Chemokines in inflammation and immunity. Immunol Today 21: 418-420.
22. Stillie R, Farooq SM, Gordon JR, Stadnyk AW, (2009) The functional significance behind expressing two IL-8 receptor types on PMN. J Leukoc Biol 86: 529-543.
23. Melero I, Vile RG, Colombo MP, (2000) Feeding dendritic cells with tumor antigens: self-service buffet or a la carte? Gene Ther 7: 1167-1170.
24. Guo J, Zhu J, Sheng X, Wang X, Qu L, et al. (2007) Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer 120: 2418-2425.
25. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, et al. (2000) Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89: 2646-2654.
26. Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, et al. (2009) Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 100: 1111-1119.
27. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, et al. (2009) Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15: 2531-2540.
28. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, et al. (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23: 1407-1413.
29. Melief CJ, (2008) Cancer immunotherapy by dendritic cells. Immunity 29: 372-383.
30. Meyer TP, Zehnter I, Hofmann B, Zaisserer J, Burkhart J, et al. (2005) Filter Buffy Coats (FBC): a source of peripheral blood leukocytes recovered from leukocyte depletion filters. J Immunol Methods 307: 150-166.
31. Gasparini G, (2001) Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2: 733-740.
32. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, et al. (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56: 641-648.
33. Balkwill F, (2004) Cancer and the chemokine network. Nat Rev Cancer 4: 540-550.
34. Gross MD, Shapiro B, Fig LM, Steventon R, Skinner RW, et al. (2001) Imaging of human infection with (131)I-labeled recombinant human interleukin-8. J Nucl Med 42: 1656-1659.
35. Rossi D, Zlotnik A, (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18: 217-242.
36. Tirapu I, Huarte E, Guiducci C, Arina A, Zaratiegui M, et al. (2006) Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res 66: 2442-2450.
37. Rabinovich GA, Gabrilovich D, Sotomayor EM, (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296.
38. Zou W, Chen L, (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8: 467-477.
39. Suarez N, Alfaro C, Dubrot J, Palazon A, Bolanos E, et al. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. Int J Cancer.
40. Belladonna ML, Orabona C, Grohmann U, Puccetti P, (2009) TGF-beta and kynurenines as the key to infectious tolerance. Trends Mol Med 15: 41-49.
41. Rutella S, Danese S, Leone G, (2006) Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108: 1435-1440.
42. Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, et al. (2004) Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 10: 950-958 Epub 2004 Aug 2029.
43. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, et al. (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2: 1096-1103.
44. Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, et al. (2007) Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204: 1037-1047.
45. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 16: 880-886.
46. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, et al. (1999) In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190: 1417-1426.
47. Kikuchi T, Moore MA, Crystal RG, (2000) Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 96: 91-99.
48. Miller PW, Sharma S, Stolina M, Butterfield LH, Luo J, et al. (2000) Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 11: 53-65.
49. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H, (1999) Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 59: 4035-4041.
50. Tirapu I, Arina A, Mazzolini G, Duarte M, Alfaro C, et al. (2004) Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer 110: 51-60.
51. Gabrilovich DI, Nagaraj S, (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
52. van Gisbergen KP, Sanchez-Hernandez M, Geijtenbeek TB, van Kooyk Y, (2005) Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med 201: 1281-1292.
53. Melero I, Arina A, Murillo O, Dubrot J, Alfaro C, et al. (2006) Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena. Clin Cancer Res 12: 2385-2389.
54. Murillo O, Dubrot J, Palazon A, Arina A, Azpilikueta A, et al. (2009) In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol 39: 2424-2436.
55. Melero I, Duarte M, Ruiz J, Sangro B, Galofre J, et al. (1999) Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 6: 1779-1784.
56. Barnden MJ, Allison J, Heath WR, Carbone FR, (1998) Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 76: 34-40.